NHS
Barnsley
Clinical Commissioning Group

Minutes of the meeting of the AREA PRESCRIBING COMMITTEE held on Wednesday, 9th February 2022 via MS Teams

MEMBERS:

Chris Lawson (Chair)	Head of Medicines Optimisation (Barnsley CCG)
Professor Adewale Adebajo	Associate Medical Director (Medicines Optimisation) on behalf of the Medical Director (BHNFT)
Tom Bisset	Community Pharmacist (LPC)
Dr Mehrban Ghani (from 22/30)	Chair, Barnsley Healthcare Federation CIC, representing the Primary Care Networks (PCNs)
Dr Rebecca Hirst	Palliative Care Consultant (Barnsley Hospice)
Dr Jeroen Maters	General Practitioner (LMC)
Dr Abdul Munzar	General Practitioner (LMC)
Mark Payne	Lead Pharmacist (SWYPFT)
Mike Smith	Chief Pharmacist (BHNFT)

IN ATTENDANCE:

Nicola Brazier	Administration Officer (Barnsley CCG)
Lauren Clarke	Senior Pharmacist, Interface (BHNFT)
Deborah Cooke	Lead Pharmacist (Barnsley CCG)
Joanne Howlett	Medicines Management Pharmacist (Barnsley CCG)
Gillian Turrell	Lead Pharmacist (BHNFT)

APOLOGIES:

Dr Kapil Kapur	Consultant Gastroenterologist (BHNFT)

ACTION BY

APC 22/25 QUORACY

The meeting was quorate.

APC 22/26 DECLARATIONS OF INTEREST RELEVANT TO THE AGENDA

The Chair invited declarations of interest relevant to the meeting agenda. The Head of Medicines Optimisation declared that she signs a variety of rebate agreements on behalf of the CCG, none of which were applicable to today's agenda, noting that there is no personal financial gain and all savings from rebates schemes are re-invested into other local health services. The rebates are all in line with PrescQIPP guidance and a full list is available on the website.

There were no further declarations of interest to note.

APC 22/27 DRAFT MINUTES OF THE MEETING HELD ON 12th JANUARY 2022

The minutes were accepted as an accurate record of the meeting.

APC 22/28 MATTERS ARISING AND APC ACTION PLAN

22/28.1 Chapter 4: CNS Pain & Neurology (morphine injection strengths)

Following concern around the morphine injection strength requested for a patient discharged from BHNFT, the Lead Pharmacist, BHNFT was obtaining feedback from the pain specialists around the morphine injection strengths used at the Trust. This was discussed internally

but as the Trust use the 15mg strength in theatres, and that the hospice may need access to this strength, this would remain on formulary. It was confirmed that patients would not be discharged on this strength and that measures could be put in place to ensure it doesn't come out to primary care.

It was agreed to obtain further detail regarding the original query/concern to put necessary measures in place.

Agreed action: -

- The original query raised in primary care would be looked at in more detail and agreed actions would be fed back to the Committee. **CL/GT /BH**

22/28.2 Liothyronine (Referrals)

Following concerns of increasing out of region referrals, the Lead Pharmacist, BHNFT advised that following internal discussions, she would be approaching the endocrinologists for help to produce robust guidance/a screening tool, like Sheffield to follow more of a regional approach for less disparity within the region. The Committee were advised that currently the number of patients referred from out of region was very small.

It was agreed that when the Trust have a position statement/ screening tool around prescribing in place, approved by the MMC, this would be brought back to the Committee for information; or any issues identified would be brought back to the Committee.

22/28.3 Transgender Prescribing Guidelines

The Head of Medicines Optimisation confirmed that the Committee's comments about wording being added to clarify that the guidelines were to support prescribers who chose to prescribe within their scope of practice, and around communication with the community pharmacy about change of identity, has been fed back.

In relation to the availability of advice and guidance support, particularly around endocrinology advice and guidance, it was noted that this has been escalated by the LMC to the South Yorkshire LMC who are seeking ICS advice and guidance levels of support for implementing/ supporting these guidelines. This APC action is therefore closed.

22/28.4 NICE TAs (DECEMBER 2021)

The Lead Pharmacist, BHNFT advised that the following NICE TAs **were** applicable for use at BHNFT: -

- TA752 Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- TA754 Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome

The Lead Pharmacist, BHNFT advised that the following NICE TA **was not** applicable for use at BHNFT: -

- TA753 Cenobamate for treating focal onset seizures in epilepsy

22/28.5 Lipid Position Statement

The Lead Pharmacist, BHNFT confirmed that the lipid position statement, written in 2016, can be removed from the BEST website given that the information is now out of date. Information will be updated in due course in line with the new national lipid pathway and ongoing work around local implementation of this pathway.

Action Plan - other

22/28.6 Freestyle Libre

The Head of Medicines Optimisation referred to previous discussions following the request from the local specialist diabetes nurses about wanting to widen the criteria around the offer of Freestyle Libre within the pathway. This was escalated and discussed with Heads of Medicines Management and other specialist nursing services from across SY&B, who maintain their position as per the guidance.

The MMT have become aware that several requests are still coming through to GPs, despite no change to the criteria within the Barnsley Freestyle Libre guidance. The Head of Medicines Optimisation will write to Dr Uchegbu, Consultant Physician in Endocrinology and Diabetes, BHNFT and the DSNs to update them around the position of Freestyle Libre and reiterate the criteria within the pathway.

Agreed action: -

- The Head of Medicines Optimisation to write to Dr Uchegbu and the DSNs (cc Lead Pharmacist, BHNFT). **CL**

APC 22/29 PHYLLOCONTIN® UPDATE

Following the discontinuation of Phyllocontin® approximately 12 months ago, the Committee agreed in October 2021 that any remaining reviews (around 340 patients) would be undertaken in primary care. The Lead Pharmacist, Barnsley CCG confirmed that this work has been completed, noting that only a very small number of patients remain on Phyllocontin® and for those patients, conversations have been held with the local pharmacies to ensure stock is in place.

An out of stock issue with Uniphyllin® 400mg was reported and this would be taken back to the MMT to ensure recorded on the spreadsheet in order to monitor the situation. **DC**

***Post meeting note**: Stock issue subsequently resolved February 2022.*

APC 22/30 DOACS NATIONAL PROCUREMENT

The Lead Pharmacist, Barnsley CCG brought the national framework for information and for the Committee to decide what action might need to be taken following on from this in terms of our guidance and formulary. NHS England have launched the national DOAC framework agreement with the aim to make treatment with DOACs more affordable as more patients are diagnosed with AF and treated.

It was agreed in the last meeting that a note would be added to the local anticoagulation in NVAF guidance acknowledging the updated NICE guidance that positions DOACs first line. It was highlighted to

the Committee that within the national framework under the treatment section, whilst all DOACs should remain available because there is a positive TA for each of them, it does state that when patients are commenced treatment, clinicians should use edoxaban where this is clinically appropriate and if edoxaban is contraindicated or not clinically appropriate for the individual patient then subject to the criteria in the TA clinicians should consider rivaroxaban first, then apixaban or dabigatran.

The patent expiry dates included in the framework were noted.

Prescribing data was presented, noting that edoxaban was used quite infrequently compared to the others and that apixaban was driving the prescribing.

The Committee would be supportive of the NHS England approach if able to support the first line edoxaban but we would need to look at this in terms of safety and what is best for the patients locally.

APC 22/31 BEOVU®

The Head of Medicines Optimisation referred to the alert in the January 2022 MHRA Drug Safety Update presented at APC 22/45, noting that ophthalmologists were informed of the new recommendations in a letter in November 2021.

The Head of Medicines Optimisation however sought feedback from BHNFT colleagues about what information the ophthalmologists had received and that they were aware of the information published around the allergic aspects to Beovu®.

It was noted that Lucentis® has been in use for many years and is a drug that we're relatively assured of in terms of safety, noting that the biosimilar for Lucentis® was expected to be available in April 2022.

The Chief Pharmacist, BHNFT had not discussed this with Miss Firan, Consultant Ophthalmologist, however felt certain that communication around the safety alert was received and considered. It was noted that in response to COVID, the service has managed to treat patients with a 12 weekly injection and reconfigured the way the clinic runs based on 12 weekly patient contact and this would need to be taken into consideration as Lucentis® needs to be given more frequently than this.

Considering information shared in the January 2022 MHRA Drug Safety Update, it was agreed further discussion at the APC was not required, however, the Head of Medicines Optimisation would meet with Miss Firan, Consultant Ophthalmologist to understand the service pathway including frequency of attendance.

Agreed action: -

- The Head of Medicines Optimisation to contact Miss Firan to arrange a meeting, copying the Chief Pharmacist and Lead Pharmacist into any email correspondence. **CL**

APC 22/32 POSSIBLE ALTERNATIVES TO UNLICENSED SPECIALS (UPDATE)

The Medicines Management Pharmacist presented the updated guidance noting information had been added to the introduction in response to comments received from the LMC to clarify that the options within the table were listed in line with the MHRA hierarchy of risk, but choice should be made on an individual patient basis.

Additional wording has been added around GP practices sharing information with the community pharmacy when prescribing off-license; and more information added around glycopyrronium bromide, noting that there are numerous different Drug Tariff manufactured specials (unlicensed preparations).

The Committee approved the updated guidance.

APC 22/33 CALCIUM AND VITAMIN D FORMULARY CHOICES (UPDATE)

The Medicines Management Pharmacist presented the updated guidance with an accompanying summary of changes, noting that the options on the formulary will be updated to match the guidance with the lines of therapy choices.

There was a discussion around maintenance dose guidance for community pharmacy and it was agreed to recommended aiming for 1000iu daily which is within the range in the guidance.

It was noted that patients are encouraged to buy vitamin D products over the counter, however it was reported that when patients receive these on prescription whilst in hospital, following discharge these are listed as a repeat medication. The Lead Pharmacist, BHNFT would highlight this issue within the Trust and the Lead Pharmacist, SWYPFT would also highlight this issue on the SWYPFT wards.

An issue was reported that when patients are discharged on a loading dose, they are advised when finished to see their GP for a vitamin D level check and to be managed accordingly which is not in line with the guidance. The Lead Pharmacist, BHNFT would highlight this issue within the Trust and would recirculate the guidance.

Subject to adding maintenance dose information for community pharmacy, the Committee approved the updated guidance.

Agreed actions: -

- Maintenance dose information for community pharmacy to be added. **JH**
- The Lead Pharmacist, BHNFT to highlight the issues above within the Trust and recirculate the guidance. **GT**
- The Lead Pharmacist, SWPFT to highlight the issue above on the SWYPFT wards. **MP**

APC 22/34 OSTEOPOROSIS DRUG HOLIDAY GUIDELINES FOR GPS (UPDATE)

The Senior Interface Pharmacist, BHNFT presented the updated guidelines, updated in line with the Management of Osteoporosis and Fragility Fracture Risk Guideline approved at the last meeting. The

same changes have been made including the removal of ibandronic acid as this is grey on the formulary and the removal of strontium ranelate due to the side-effects and that it is no longer used at BHNFT.

The treatment algorithm has been amended, making it more in line with the NOGG guidelines.

Subject to approval from the LMC, the Committee approved the updated guidelines.

Agreed action: -

- The guidelines to be shared with Dr Bannon for approval from the LMC. **LC**

APC 22/35 NEW PRODUCT APPLICATION FORM (UPDATE)

The Lead Pharmacist, Barnsley CCG presented the updated new product application form which was due a routine update. The form has been circulated to Committee members for comment and the track changes, which were relatively minor were highlighted.

The Committee approved the updated new product application form.

APC 22/36 SHARED CARE GUIDELINES / AMBER G SHARED CARE GUIDELINES

22/36.1 Metolazone Amber G Guideline (new)

The Senior Interface Pharmacist, BHNFT presented the guideline to the Committee.

There was a request for extra monitoring information to be added, especially at initiation of the medication.

Subject to the inclusion of additional monitoring information and approval from the LMC, the Committee approved the guideline.

Agreed action: -

- The guideline would be sent to the cardiologists for feedback and the extra monitoring information to be added would be shared with LMC representatives for approval. **LC**

22/36.2 Clomifene for the treatment of women with infertility due to ovulatory dysfunction Amber G Guideline (new)

The Senior Interface Pharmacist, BHNFT presented the guideline with no comments from the Committee. Subject to approval from the LMC, the Committee approved the guidelines.

Agreed action: -

- The guideline to be shared with Dr Bannon for approval from the LMC. **LC**

22/36.3 Desmospray (Desmopressin Nasal Spray) for diabetes insipidus Amber G Guideline (new)

The Senior Interface Pharmacist, BHNFT presented the guideline with no comments from the Committee. Subject to approval from the LMC, the Committee approved the guideline.

Agreed action: -

- The guideline to be shared with Dr Bannon for approval from the LMC. **LC**

22/36.4 Amber Shared Care Guideline for Dantrolene (for the treatment of chronic severe spasticity of voluntary skeletal muscle in adults) (new)
The Senior Interface Pharmacist, BHNFT presented the guideline with no comments from the Committee. Subject to approval from the LMC, the Committee approved the guideline.

Agreed action: -

- The guideline to be shared with Dr Bannon for approval from the LMC. **LC**

APC 22/37 FORMULARY REVIEWS

22/37.1 Formulary Review Plan (for information)
The Lead Pharmacist, Barnsley CCG presented the formulary review plan for information, which has been updated with revised dates for the remaining sections. The anaesthesia section review date is still to be confirmed. Chapter 14 has been brought to this month's meeting.

The volume of work undertaken when reviewing the formulary chapters was acknowledged by the Chair of the Committee.

22/37.2 Chapter 14: Immunological Products and Vaccines
The Senior Interface Pharmacist, BHNFT presented the review with minor changes, including new links/guidelines; additions to the traffic light list and updating COVID vaccine information. It was noted that changes recommended at the previous review had not been actioned, but it was confirmed that these changes have now been applied.

The Committee approved the formulary review for Chapter 14: Immunological Products and Vaccines.

APC 22/38 NEW PRODUCT APPLICATION LOG

The log was received for information and noted.

The Lead Pharmacist, SWYPFT raised that lurasidone, currently non-formulary provisional amber may be brought to the Committee to consider a formulary status change to amber. It was agreed that this would be discussed outside of the meeting and brought back to the next meeting.

Agreed action: -

- Lurasidone to be discussed outside of the meeting. **CL/DC/ JH/MP**

APC 22/39 NEW PRODUCT APPLICATIONS

The Lead Pharmacist, Barnsley CCG presented the new product applications for Bevespi® and Trixeo® to be considered together due to their similarities. These have been submitted by an ANP in primary care and both independent reviews have been prepared by one of the Medicines Management Pharmacists.

22/39.1 Bevespi®

Bevespi® is a LAMA/LABA inhaler which was launched in the UK in January 2021. The recommended dose is two inhalations twice daily (morning and evening). The drugs within both inhalers are well established and therefore it was to look more at the devices and how potentially they could sit compared to other options.

NICE highlight several factors that should be taken into consideration when selecting an inhaler for an individual patient, one being the patient's preferences and ability to use the inhaler.

The efficacy was noted, compared to the individual components, and did demonstrate improved lung function. There are currently 3 LABA/LAMAs on formulary, 2 dry powder inhalers and 1 inhalation spray (Spiolto®). This is a metered-dose inhaler, and the applicant has proposed that the potential advantage is that it can be used with an aero chamber, providing an alternative device if the dry power or inhalation spray are not appropriate.

The costs were noted, all the LAMA/LABAs cost the same.

It was noted that Bevespi® was not currently in the local formularies for other South Yorkshire areas, both Bevespi® and Trixeo® are included in a number of formularies nationally.

In summary, Bevespi® is an MDI which can be used with a spacer. It does have a higher carbon footprint than other LAMA/LABAs currently on the formulary, and the cost is comparable.

It was agreed that feedback would be obtained from the respiratory consultants for their views on Bevespi®, noting that Spiolto® has a lower carbon footprint and that unless feedback from the respiratory consultants highlights any new advantages for using Bevespi®, then the new product application was likely to be declined.

Agreed actions: -

- Feedback to be obtained from the respiratory consultants for their views around potential place in therapy. **GT/AA**
- A decision regarding Bevespi® will be made in the next meeting after feedback has been obtained from the respiratory consultants. **CL**

22/39.2 Trixeo®

Trixeo® is a triple inhaler with glycopyrronium bromide, formoterol fumarate dihydrate and budesonide and it was noted that triple inhalers are included within the NICE COPD Guidance. The recommended dose is two inhalations twice daily (morning and evening). The evidence presented indicates improved lung function and generally superior compared to LAMA/LABA and LABA/ICS. In the ETHOS trial, Trixeo® did reduce exacerbation rate compared to those combinations (dual therapies).

The current formulary options were noted, 2 DPIs and one MDI inhaler (which has a slightly lower carbon footprint than Trixeo®). The cost is comparable.

The Committee were in support of adding Trixeo® to the formulary due to the lower carbon footprint, however feedback would be obtained from the respiratory consultants about adding this in place of Trimbow® MDI.

Agreed action: -

- Feedback to be obtained from the respiratory consultants for their views about possibly removing Trimbow® MDI from the formulary. **GT/AA**

APC 22/40 BARNSLEY APC REPORTING

22/40.1 APC Reporting December 2021

The Lead Pharmacist, Barnsley CCG presented the enclosure showing reports received directly into the APC reporting mailbox for the month of December 2021. There were 19 APC reports received. Positive and negative feedback was shared on the new format of the D1s.

22/40.2 APC Reporting December 2021 Key Themes

The summary report was presented, showing 63 reports in total, including 19 APC reports and 44 interface queries received directly within BHNFT for the month of December 2021. Since bringing the number of interface queries to the Committee, the number on average per month is around 60-70.

The main key themes were noted including 50% being associated with D1 communication or other hospital communication issues. Details relating to several significant issues were shared and highlighted including D1 formatting issues and D1's not printed and completed at the time of discharge.

There was a lengthy discussion around the D1 issues, noting that formatting issues experienced in late December/early January have been resolved, however, new formatting issues have been reported by primary care, as well as reports that D1s have not been received by primary care or that multiple copies of D1s have been received. Examples were shared. These issues have been highlighted to the Trust, noting that the issue is affecting discharges from a small number of wards. BHNFT were currently working through a process to resolve these issues and additional steps have been put in place on the new Care Flow Discharge platform.

The Chief Pharmacist, BHNFT acknowledged the ongoing challenges as the Trust turn EPMA on for in-patients in the test areas which appears to be affecting the discharges. Assurance was given that the Clinical Systems Team can resolve the issues when the Trust are notified of individual reports of formatting issues. The issue raised around overspill of long drug names into the dosage section would be escalated to the EPMA Lead.

Primary care also reported an issue being seen on the EMIS system with the D1s, noting no issue when viewing information electronically, however if printed, the D1 was not readable.

Acknowledging that some of these concerns have been raised over a number of years and new issues being reported following the introduction of new systems aimed to improve patient safety, it was agreed that a meeting would be arranged with MMT and BHNFT colleagues, including BHNFT IT representatives to discuss and demonstrate some of the issues seen in primary care.

Agreed actions:

- The Lead Pharmacist, Barnsley CCG to share example of overspill of long drugs names with the Chief Pharmacist and Senior Interface Pharmacist. **DC**
- The Chief Pharmacist, BHNFT to escalate issue of overspill of long drug names to the EPMA Lead. **MS**
- Meeting to be arranged to discuss D1 IT issues. **NB**

22/40.3 APC Reporting December 2021 Interface Issues

The enclosure detailing the interface queries received directly within BHNFT was received and noted.

APC 22/41 NEW NICE TECHNOLOGY APPRAISALS (JANUARY 2022)

22/41.1 NICE TAs January 2022

The Lead Pharmacist, BHNFT advised that the following NICE TAs **were** applicable for use at BHNFT: -

- TA757 Cabotegravir with rilpivirine for treating HIV-1
- TA599 (update) Sodium zirconium cyclosilicate for treating hyperkalaemia

The Lead Pharmacist, BHNFT advised that the following NICE TAs **were not** applicable for use at BHNFT: -

- TA759 Fostamatinib for treating refractory chronic immune thrombocytopenia (not recommended)
- TA760 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
- TA761 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

The Lead Pharmacist, BHNFT **would advise** if the following NICE TA was applicable for use at BHNFT: - **GT**

- TA758 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy

***Post meeting note**: it was confirmed that TA758 **was not** applicable for use at BHNFT.*

22/41.2 Feedback from BHNFT Clinical Guidelines and Policy Group

There was nothing relevant to report.

22/41.3 Feedback from SWYPFT NICE Group

There was nothing relevant to report.

APC 22/42 FEEDBACK FROM THE MEDICINES MANAGEMENT GROUPS

22/42.1 Primary Care Quality & Cost-Effective Prescribing Group (QCEPG)

The Group have not met since the last APC meeting.

22/42.2 BHNFT
There was nothing additional to report back other than the D1 issues already discussed above.

22/42.3 SWYPFT Drug and Therapeutics Committee
There was nothing additional to report back other than lurasidone discussed above at 22/38.

22/42.4 Community Pharmacy Feedback
There was nothing to report.

22/42.5 Wound Care Advisory Group
The group have not met since the last APC meeting, however the Head of Medicines Optimisation advised that issues have been identified with availability of products within the Trust and also the training of nurses in terms of changing garments and compression bandaging for lymphoedema patients. The Wound Care Nurse Specialist is working with the Trust to resolve these issues and an update would be brought back to the Committee after the next Wound Care Advisory Group meeting.

APC 22/43 ISSUES FOR ESCALATION TO THE QUALITY & PATIENT SAFETY COMMITTEE (Q&PSC)
It was agreed that APC Reporting, D1 issues and DOACs would be escalated to the Q&PSC. **CL**

APC 22/44 SPS NEW MEDICINES NEWSLETTER (DECEMBER 2021)
The Committee assigned the following classifications to the products listed below: -

- Fenfluramine (Fintepla®) - non-formulary provisional red
- Glucagon (Ogluo®) - non-formulary provisional grey
- Tucatinib (Tukysa®) - non-formulary provisional red

The Lead Pharmacist, SWYPFT advised that EMA have adopted a positive opinion for a new form of risperidone injection, noting the current risperidone injectable has a red traffic light classification. The Committee would await notification of this via the SPS New Medicines Newsletter before assigning a traffic light classification.

APC 22/45 MHRA DRUG SAFETY UPDATE (JANUARY 2022)
The update was noted with the following information highlighted relevant to primary care: -
Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals
Maintenance doses of brolucizumab (after the first 3 doses) should not be given at intervals of less than 8 weeks apart.

COVID-19 vaccines and medicines: updates for January 2022
Recent information relating to COVID-19 vaccines and medicines that has been published since the December 2021 issue of Drug Safety Update, up to 13 January 2022.

Noted the approval of Paxlovid - oral COVID-19 antiviral treatment.

Noted the approved new paediatric formulation of the Pfizer/BioNTech COVID-19 vaccine for children aged 5 to 11 years. The Lead Pharmacist, BHNFT confirmed that this was part of NMAB and antiviral and would be managed by the CMDU. She was currently in the process of pulling together the required internal forms.

APC 22/46 REGIONAL MEDICINES OPTIMISATION COMMITTEE (RMOC)

There was nothing relevant to report.

APC 22/47 SOUTH YORKSHIRE AREA PRESCRIBING COMMITTEE MINUTES (FOR INFORMATION)

The minutes from NHS Sheffield CCG (18th November 2021) were received and noted.

APC 22/48 ANY OTHER BUSINESS

22/48.1 QUIT/In-Patient Smoking Cessation

The Lead Pharmacist, SWYPFT advised that people who go to non-SWYPFT providers for their mental health care and on discharge are prescribed nicotine replacement may not be getting the referral on to the appropriate community provider, and therefore asked if there was an opportunity to work with the MMT clinical pharmacists, to aid a pathway referral when seeing nicotine replacement for someone on a discharge prescription.

Further information would be provided by email to aid discussions with the MMT Clinical Pharmacist Leads.

Agreed actions: -

- The Lead Pharmacist, SWYPFT to send further information by email to the Head of Medicines Optimisation and Lead Pharmacist. **MP**
- Discussions to take place with the MMT Clinical Pharmacist Leads when information received. **CL/DC**

APC 22/49 DATE AND TIME OF THE NEXT MEETING

The time and date of the next meeting was confirmed as Wednesday, 9th March 2022 at 12.30 pm via MS Teams.